Certified by Founder Lodge
Akribion Therapeutics
Germany - Zwingenberg
START UP
1 Disclosed Funding Rounds $8,275,080
0 Participating Investments
-
Founded date
2024
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Its G-dase® E payload has the ability to kill cells by shredding DNA and R
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| February, 04 ,2025 | Seed | $8,275,080 |
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Avallon AI (YC X25) | $4,600,000 | (Nov 7, 2025)
Kaizen Labs | $12,000,000 | (Nov 7, 2025)
SiteLabs | $2,000,000 | (Nov 7, 2025)
Fintary | $10,000,000 | (Nov 7, 2025)
Inception | $50,000,000 | (Nov 7, 2025)
